SELLAS Life Sciences and 3D Medicines Announce Exclusive License Agreement for Development and Commercialization of Galinpepimut-S (GPS) and GPS+ in Greater China
- SELLAS to Potentially Receive Up To $202 Million, Inclusive of $7.5 Million Upfront License Fee and $8 Million Near-term...